Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-26T21:59:22.717Z Has data issue: false hasContentIssue false
  • English
  • Français

The future for long chain n-3 PUFA in the prevention of coronary heart disease: do we need to target non-fish-eaters?

Published online by Cambridge University Press:  16 May 2017

W. L. Hall
W. L. Hall*
Affiliation:
Diabetes and Nutritional Sciences Division, Faculty of Life Sciences and Medicine, King's College London, London, UK
*
Corresponding author: Dr W. L. Hall, email wendy.hall@kcl.ac.uk
Rights & Permissions [Opens in a new window]

Abstract

Dietary guidelines in many countries include a recommendation to consume oily fish, mainly on the basis of evidence from prospective cohort studies that fish consumption is cardioprotective. However, average intakes are very low in a large proportion of the UK population. Some groups, such as vegans and vegetarians, purposely omit fish (along with meat) from their diet resulting in zero or trace intakes of long chain (LC) n-3 PUFA. Although the efficacy of dietary fish oil supplementation in the prevention of CVD has been questioned in recent years, the balance of evidence indicates that LC n-3 PUFA exert systemic pleiotropic effects through their influence on gene expression, cell signalling, membrane fluidity and by conversion to specialised proresolving mediators; autacoid lipid mediators that resolve inflammatory events. The long-term impact of reduced tissue LC n-3 PUFA content on cardiovascular health is surprisingly poorly understood, particularly with regard to how low proportions of LC n-3 PUFA in cell membranes may affect cardiac electrophysiology and chronic inflammation. Randomised controlled trials investigating effects of supplementation on prevention of CHD in populations with low basal LC n-3 PUFA tissue status are lacking, and so the clinical benefits of supplementing non-fish-eating groups with vegetarian sources of LC n-3 PUFA remain to be determined. Refocusing dietary LC n-3 PUFA intervention studies towards those individuals with a low LC n-3 PUFA tissue status may go some way towards reconciling results from randomised controlled trials with the epidemiological evidence.

Keywords

n-3 PUFACHDHeart rate variabilityInflammationLipid mediators
Type
Conference on ‘New technology in nutrition research and practice’
Information
Proceedings of the Nutrition Society , Volume 76 , Issue 3 , August 2017 , pp. 408 - 418
Check for updates
Copyright
Copyright © The Author 2017 

Seafood has been a key component of human diets for thousands of years, and is rich in long chain (LC) n-3 PUFA, EPA (20 : 5n-3) and DHA (22 : 6n-3). Endogenous synthesis of EPA can occur in the human body to a limited extent when there is a dietary supply of the shorter chain, plant-derived n-3 PUFA, α-linolenic acid (ALA, 18 : 3n-3), but further conversion to DHA appears to occur only on a very small scale( Reference Burdge 1 ). Microscopic, single-celled marine organisms carry out de novo synthesis of LC n-3 PUFA resulting in concentrated amounts of EPA and DHA in the seafood that is commonly consumed by human subjects further up the marine food chain. In fact, the role of microalgae as primary producers of EPA and DHA may have been a key driver that enabled the evolutionary adaptation response of early Homo sapiens to environmental pressures. A plausible theory posits that an increased reliance on marine resources by early human subjects began in Africa about 140 000 years ago and allowed the modern human brain to grow rapidly due to a ready supply of dietary DHA( Reference Bradbury 2 – Reference Broadhurst, Cunnane and Crawford 4 ). DHA comprises approximately 40 % of total PUFA in the mammalian central nervous system( Reference Broadhurst, Cunnane and Crawford 4 ) and proponents of the marine/brain theory postulate that rapid encephalisation and increasing neural plasticity opened the way to behavioural innovations that enabled population expansion along the African coast and beyond( Reference Crawford, Bloom and Broadhurst 5 ).

An adequate supply of LC n-3 PUFA is vital for development and maintenance of the nervous system, a topic that has been comprehensively reviewed elsewhere( Reference Michael-Titus and Priestley 6 – Reference Dyall 9 ). A functioning central and peripheral nervous system, particularly the autonomic nervous system comprising sympathetic and parasympathetic nerves, is also essential for cardiovascular health, including homeostasis of blood pressure and heart rate (HR) by innervation of blood vessels and the pacemaker respectively. Marine LC n-3 fatty acids profoundly influence cardiovascular function (HR, blood pressure), by influencing neuronal function in the hypothalamus, sympathetic and parasympathetic neurons and the intrinsic cardiac nervous system by neurotrophic and neuroprotective mechanisms( Reference Robson, Dyall and Sidloff 10 ), including anti-inflammatory mechanisms( Reference Calder 11 , Reference Bazan, Molina and Gordon 12 ). Accumulated evidence to date suggests that dietary fish consumption is protective against cardiac mortality( Reference Zheng, Huang and Yu 13 ) and the potentially anti-arrhythmic effects of LC n-3 PUFA at relatively low doses are likely to be a significant contributor to these observed effects( Reference Albert, Campos and Stampfer 14 , Reference Marchioli, Barzi and Bomba 15 ).

Organisations with the authority to set dietary guidelines across the world are in agreement that inclusion of fish in the diet, particularly oily fish, or supplemental fatty acids derived from fish, is likely to be protective against CVD( 16 ). The link between marine fatty acids and CVD has been intensively investigated since the earliest reports appeared in the latter half of the last century of associations between high LC n-3 PUFA intakes and low rates of CVD in Canadian and Greenland Inuits( Reference Sinclair 17 – Reference Bang, Dyerberg and Nielsen 19 ). Epidemiological studies support the theory that fish consumption reduces the risk of CHD mortality( Reference Zheng, Huang and Yu 13 , Reference Mozaffarian and Wu 20 ) and meta-analyses of studies measuring blood or tissue levels of EPA + DHA at baseline have shown inverse associations with risk of coronary events( Reference Chowdhury, Warnakula and Kunutsor 21 ). The lack of effect in more recent primary and secondary prevention randomised controlled trials of fish oil supplementation( Reference Rizos, Ntzani and Bika 22 ), in contrast to earlier well-known trials( Reference Marchioli, Barzi and Bomba 15 , Reference Burr, Fehily and Gilbert 23 , Reference Tavazzi, Maggioni and Marchioli 24 ) has been debated at length( Reference von Schacky 25 – Reference Rice, Bernasconi and Maki 28 ). Factors such as reduced bioavailability of supplemental oils if consumed with low-fat meals or no food at all, concomitant medications obscuring therapeutic benefit (e.g. statins) and the amount of EPA and DHA already present in the body tissues, may have been critical determinants of clinical efficacy. A critical question is whether individuals with a risk profile indicating increased cardiovascular risk due to a low EPA and DHA tissue status, might benefit more from dietary LC n-3 PUFA supplementation than those whose tissue fatty acid profile is relatively enriched with EPA and DHA. Only 23 % of UK adults aged 19–64 report consuming oily fish and if this is accurate, it presents the possibility that a large proportion of the UK population may have sub-optimal concentrations of LC n-3 PUFA in their tissues and may be at increased risk of CHD mortality( Reference Zheng, Huang and Yu 13 ). Dietary intakes of fish and fish oil fatty acids vary widely for a variety of reasons, including lifestyle choices, for example vegetarianism, access to food/food security, food preferences and religious dietary restrictions. Furthermore, individual dietary requirements for fish oil fatty acids are likely to vary due to genetic variation (for example polymorphisms in the desaturase and elongase genes( Reference Smith, Follis and Nettleton 29 – Reference AlSaleh, Maniou and Lewis 31 )) and possibly background inflammatory burden, which may also be partly genetically determined( Reference Grenon, Conte and Nosova 32 ). The aim of this review is to examine what we know about the consequence of low dietary EPA and DHA intakes and to consider what the cardiovascular health impact might be in otherwise healthy populations.

ω-3 Index and cardiovascular health

A widely accepted method to assess an individual's medium-term dietary intakes of LC n-3 PUFA, is by measuring the percentage of erythrocyte membrane fatty acids (erythrocyte phospholipids) that are EPA and DHA, which correlates closely with the EPA + DHA content in cardiac tissue( Reference Harris, Sands and Windsor 33 ). Proportions of EPA + DHA in erythrocyte phospholipids have been identified as an independent predictor of CVD risk( Reference Harris and Von Schacky 34 , Reference Kleber, Delgado and Lorkowski 35 ). Erythrocyte EPA + DHA as a % of total erythrocyte fatty acids is termed the ω-3 index, with ≥8 % considered to be associated with the maximum protective effect( Reference Harris and Von Schacky 34 ). Incorporation of supplemented EPA + DHA into erythrocyte membranes occurs in a dose–response fashion and significant increases can be measured over a supplementation period of 2–12 months at relatively low doses akin to intake of 1–4 portions of oily fish per week( Reference Browning, Walker and Mander 36 ). The effects of age and sex on the efficiency of incorporation of supplemental EPA and DHA in blood cells and plasma fractions seem to be relatively minor( Reference Walker, Browning and Mander 37 ), but there may be an increased efficiency of uptake in individuals with lower baseline intakes of LC n-3 PUFA( Reference Cao, Schwichtenberg and Hanson 38 ) and potentially at times of greater need such as during pregnancy( Reference Dunstan, Mori and Barden 39 ). Reported average ω-3 indices vary widely in human populations that are identified as being omnivorous, most likely representing the fact that meat-consumers who eat very little fish will have much lower proportions of EPA and DHA in their membrane lipids than meat-consumers who also regularly consume fish, whereas reported ω-3 indices in vegans are distinctly lower compared with meat and fish-eaters (Table 1). Observational evidence suggests that low whole blood or erythrocyte membrane levels of EPA and DHA are associated with a greater risk of sudden cardiac death, primary cardiac arrest, acute coronary syndrome( Reference Albert, Campos and Stampfer 14 , Reference Siscovick, Raghunathan and King 40 , Reference Block, Harris and Reid 41 ) and a meta-analysis of prospective cohort studies that measured circulating fatty acids showed associations between higher EPA and DHA and lower relative risks of coronary outcomes( Reference Chowdhury, Warnakula and Kunutsor 21 ).

Table 1. Erythrocyte EPA and DHA (% or absolute concentrations) of meat- and fish-consumers (omnivores), vegetarians and vegans

Wt%, weight percentage of the sum of fatty acids; mol%, mole percentage of the sum of fatty acids.

* A vegetarian was defined as someone who ate no meat and not more than one fish meal a month.

Cardiovascular health of populations with low ω-3 index: vegetarians and vegans

Evidence from prospective cohort studies with a high proportion of vegetarians and vegans suggests that they are less likely to develop CHD than meat- and fish-consumers. For example, a 1999 meta-analysis of five prospective studies (USA, UK, Germany) reported that vegetarians had 24 % lower mortality from CHD (specific to those who followed diet for >5 years)( Reference Key, Fraser and Thorogood 42 ). Additional prospective cohorts included in more recent meta-analyses agreed with earlier findings( Reference Huang, Yang and Zheng 43 , Reference Kwok, Umar and Myint 44 ). Reduced risk of CHD appears to be driven by lower blood LDL cholesterol, blood pressure and possibly lower BMI in vegans/vegetarians( Reference Key, Appleby and Rosell 45 – Reference Appleby, Davey and Key 47 ). Taking this evidence at face value it appears that a vegetarian/vegan diet may be a cardio-protective diet. It has been suggested that there seems to be a minimum basal rate of conversion of ALA to DHA, which is sufficient to maintain cardiovascular health where dietary sources of pre-formed LC n-3 PUFA are lacking( Reference Sanders 48 , Reference Sanders 49 ). Furthermore, authors of an observational study, using statistical estimates of ALA to longer chain n-3 PUFA conversion rates, suggested that conversion might actually be increased in non-fish eaters compared with fish-eaters. This would account for the relatively low margin of difference in ω-3 indices of fish-eaters compared with non-fish eaters( Reference Welch, Shakya-Shrestha and Lentjes 50 ), although conversion rates to DHA specifically were not clear.

Closer inspection of the observational evidence for coronary risk in vegetarians/vegans, raises the question of whether it is valid to translate these findings to the wider population. Vegetarian/vegan cohorts vary in their motivations for dietary choice (religious, health, animal welfare), which may converge with other distinct lifestyle behaviours that may affect cardiovascular health (physical exercise, practising mindfulness/meditation/prayer, prevalence of alcohol and drug use). This concern seems particularly pertinent to the Seventh Day Adventist cohorts. Kwok et al. applied sub-group testing in their meta-analysis of seven prospective cohort studies that evaluated mortality and clinical cardiovascular outcomes in vegetarian populations compared with non-vegetarian controls and revealed that the overall pooled difference in risk of cardiac events was mainly driven by the Seventh Day Adventist cohorts( Reference Kwok, Umar and Myint 44 ), suggesting that the results from this particular population might not be generalisable to other populations. Furthermore, the definition of vegetarian in Seventh Day Adventist cohorts tends to be inconsistent with the generally accepted definition of eating no meat or fish. Seventh Day Adventist cohorts incorporated into the pooled analyses( Reference Key, Fraser and Thorogood 42 , Reference Kwok, Umar and Myint 44 ) included those who ate meat <1/week or less with no mention of what their fish intakes were( Reference Snowdon 51 , Reference Beeson, Mills and Phillips 52 ), or were otherwise not clearly defined( Reference Berkel and de Waard 53 ). It is therefore possible that the Adventist cohorts were also fish-consumers and may have had higher ω-3 indices than ‘true’ vegetarians/vegans who do not eat any fish. The more recent Adventist Health Study 2 clearly defined participants as vegans, lacto-ovo vegetarians, pesco-vegetarians, semi-vegetarians and non-vegetarians( Reference Orlich, Singh and Sabaté 54 ). The results of Adventist Health Study 2 showed that the reduced risk in CHD mortality was not quite statistically significant (hazard ratio 0·81, 95% CI 0·64, 1·02) for all vegetarians combined. Further analysis of dietary sub-groups revealed that the reduced risk was significant in pesco-vegetarians when both sexes were combined (hazard ratio 0·65, 95% CI 0·43, 0·97) but not vegans (hazard ratio 0·90, 95% CI 0·60, 1·33) or lacto-ovo vegetarians (hazard ratio 0·90, 95% CI 0·76, 1·06).

The UK vegetarian/vegan cohorts might be considered more generalisable to the broader population since they are not affiliated with a religious faith and may be more diverse in terms of demographics and lifestyle behaviours. Furthermore, vegetarians and vegans were clearly defined as not eating meat or fish( Reference Appleby, Davey and Key 47 , Reference Appleby, Crowe and Bradbury 55 , Reference Crowe, Appleby and Travis 56 ) and the vegetarian and vegan men from the EPIC-Oxford cohort were reported to have lower EPA and DHA proportions of total plasma fatty acids compared with omnivores, providing an objective biomarker of low fish intake( Reference Rosell, Lloyd-Wright and Appleby 57 ). Although vegetarians/vegans had a lower incidence of CHD in the UK EPIC-Oxford cohort( Reference Crowe, Appleby and Travis 56 ), there was no difference in CHD mortality compared with controls who ate meat and fish (death rate ratio 0·83, 95% CI 0·59, 1·18)( Reference Key, Appleby and Spencer 58 ). The latter study may have been statistically underpowered, but a more recent combined analysis of mortality rates (total 644 CHD deaths) reported that there was no significant difference in CHD mortality in UK vegans/vegetarians up to 90 year (nor 75 year) compared with comparable regular meat-eaters (hazard ratio 0·99, 95% CI 0·79, 1·23)( Reference Appleby, Crowe and Bradbury 55 ), who consumed meat ≥5 times/week as well as fish.

In translating these observations to the question of the cardiovascular health impact of low EPA + DHA tissue status, it is impossible to cleanly dissect the influence of dietary LC n-3 fatty acid intake from other dietary influences. For example, vegetarian/vegan diets are lower in SFA, higher in fibre, but can also be deficient in bioavailable iron, vitamin B12 and vitamin D. Low serum 25-hydroxyvitamin D concentrations are also associated with increased CVD mortality( Reference Schöttker, Jorde and Peasey 59 ). Furthermore, the nature of the comparator group is an important consideration, particularly as health-conscious participants were recruited to UK cohorts who tended to have lower intakes of dietary animal protein compared with Adventist non-vegetarian/non-vegans( Reference Crowe, Appleby and Travis 56 ). However, equivalent CHD mortality rates could alternatively signify that the vegetarian/vegan diet is also associated with other raised CHD risk factors (e.g. low ω-3 index) that might negate the otherwise cardio-protective effects of a vegetarian/vegan diet. It is hypothesised here that long-term low tissue LC n-3 PUFA levels may counterbalance the athero-protective qualities of vegetarian/vegan diets in the sum effect on overall CHD mortality risk. The implications of this for the sizeable non-fish-eating, non-vegetarian/non-vegan population are more serious. Low tissue EPA and DHA levels in a less health-conscious meat-eating population might have a more deleterious effect on cardiovascular health, such as increasing risk of cardiac arrhythmia, against the background of higher LDL-cholesterol, blood pressure and BMI. Fig. 1 summarises the counterbalance of dietary factors that may positively or negatively influence risk of CHD mortality in non-fish eaters. The next sections will address the cardiovascular risk factors that may mediate increased risk of CHD mortality in populations with very low LC n-3 PUFA intakes, including low HR variability (HRV) and a reduced capacity to regulate inflammatory responses.

Fig. 1. Theoretical schematic showing how low long chain n-3 PUFA intakes may oppose the cardioprotective effects of vegetarian/vegan diets, resulting in an equivalent risk of CHD mortality (A). The majority of the UK population eats little or no fish and may be at risk of low ω-3 status. Without the counterbalancing cardio-protective qualities of a vegetarian/vegan diet, this could lead to an increased risk of CHD mortality mediated by arrhythmia (B). Picture of artery attributed to ‘Blausen gallery 2014’( 136 ).

Heart rate variability and risk of arrhythmia

Low HRV indicates a reduced capacity to regulate HR in response to internal and external stressors and demands, and is associated with mortality after a myocardial infarction( Reference Vaishnav, Stevenson and Marchant 60 – 62 ) and risk of cardiac events in the general population( Reference Tsuji, Larson and Venditti 63 ). Low HRV is considered to be a predictor of sudden cardiac death( Reference Algra, Tijssen and Roelandt 64 ). Therefore, measurement of parameters of short- and long-term variability in heart beat intervals (RR intervals, or interbeat intervals) using Holter monitors or less intrusive HRV/accelerometry integrated chest-worn monitors (e.g. Actiheart, eMotion Faros), can be a useful non-invasive method to assess the adaptability/resilience of the heart. HRV is partly under the control of the autonomic nervous system, which receives afferent impulses from, and exerts efferent activity to, the intrinsic cardiac nervous system, which interacts with the sino-atrial node. Consequently, variability in HR reflects the sum effect of sympathetic and parasympathetic outflow. Low HRV is associated with a high degree of sympathetic activity (which raises HR thus reducing the capacity to self-regulate in response to demand) and suppressed parasympathetic activity (vagal activity slows HR). Higher LC n-3 PUFA tissue status or fish consumption has been positively associated with HRV( Reference Christensen 65 , Reference Mozaffarian, Stein and Prineas 66 ). Mixed results have been obtained in previous investigations into the effect of n-3 PUFA on HRV in healthy subjects( Reference Mozaffarian, Stein and Prineas 66 – Reference Christensen, Christensen and Dyerberg 69 ), haemodialysis patients( Reference Svensson, Schmidt and Jorgensen 70 ), subjects with previous myocardial infarction( Reference Christensen, Korup and Aaroe 71 – Reference Hamaad, Kaeng Lee and Lip 74 ) and patients with epilepsy( Reference DeGiorgio, Miller and Meymandi 75 ). These studies were typically only 12 weeks long, the durations of HR monitoring differed widely and relatively high doses of n-3 PUFA ranged from 1 to 6·6 g. Furthermore, comparisons between studies are difficult due to different HRV parameters being reported, varying study designs, and methodological inconsistencies. Nevertheless, fish oil supplementation has been shown to increase a parameter of beat-to-beat (vagally regulated) HRV in a meta-analysis of randomised controlled trials( Reference Xin, Wei and Li 76 ), supporting the role of adequate tissue EPA + DHA status in preventing arrhythmic events. Thus autonomic balance may be improved by increased EPA and DHA membrane levels, although a direct effect on pacemaker activity independently of the autonomic nervous system may also occur. Increasing LC n-3 PUFA content in rabbit cardiomyocyte membranes decreases HR in isolated hearts and reduces pacemaker activity and pacemaker current in sinoatrial node cells( Reference Verkerk, den Ruijter and Bourier 77 , Reference Billman 78 ). In accord with its effects on HRV in clinical trials, fish oil supplementation also reduces HR in human studies( Reference Mozaffarian, Geelen and Brouwer 79 ).

In summary, fish consumption and to some extent fish oil supplementation, is associated with reductions in HR and increased HRV, which would be predicted to reduce the risk of arrhythmia. However, the impact on HRV of consuming a LC n-3 PUFA-free diet was unexplored until recently, when we addressed this question in a cross-sectional study in vegans and age- and BMI-matched omnivores, measuring the average duration of interbeat intervals (the reciprocal of HR), HRV, erythrocyte phospholipid fatty acids, plasma fatty acids and oxygenated PUFA metabolites( Reference Pinto, Sanders and Kendall 80 ). Vegans had lower day-time beat-to-beat HRV and shorter day-time interbeat intervals compared with omnivores, adjusted for age, sex, BMI and physical activity levels by accelerometry. Twenty-four hour HRV was higher in vegans due to the greater night–day differences in vegans compared with omnivores, which was mainly due to the relatively lower HRV during the day rather than higher HRV at night in vegans; no differences between groups during nocturnal sleep were observed. This could indicate a greater predominance of sympathetic regulation (associated with reduced parasympathetic activity) during waking hours due to an exaggerated response to stimuli, or a direct effect of low LC n-3 PUFA membrane concentrations in cardiac cells on the pacemaker that manifested in altered cardiac function under conditions of stimulation. There were no differences in serum vitamin D or B12 status between the groups, factors which may also have impacted on HRV. Although these observations only demonstrate an associative link, n-3 PUFA tissue status is implicated as a strong candidate for being the key factor in determining the disparate HRV patterns during waking hours observed in vegans and omnivores.

Dampening and resolving inflammation

Both n-6 and n-3 PUFA in cell membranes can be metabolised into an array of pro- and anti-inflammatory metabolites that are likely to influence prevention of arrhythmia by influencing myocyte cell-signalling and also autonomic function. Chronic inflammation is the key underlying factor in the lifelong accrual of vascular lesions that eventually leads to atherosclerosis and CHD, and LC n-3 PUFA supplementation appears to improve plaque stability( Reference Thies, Garry and Yaqoob 81 ). Although the role of inflammation in initiating and propagating atherosclerosis is at the crux of CHD, chronic inflammation probably also increases coronary risk independently of atherosclerosis by impairing neuronal function( Reference Dyall and Michael-Titus 82 ) and myocyte membrane properties( Reference Papaioannou, Verkerk and Amin 83 ), thereby having a direct influence on cardiac electrophysiology and risk of arrhythmia( Reference Lanza, Sgueglia and Cianflone 84 , Reference Malave, Taylor and Nattama 85 ). LC n-3 PUFA levels in plasma and erythrocytes are inversely associated with circulating markers of inflammation (C-reactive protein, IL-6, IL-1 receptor antagonist, TNF receptor 2, transforming growth factor-β)( Reference Farzaneh-Far, Harris and Garg 86 – Reference Fontes, Rahman and Lacey 88 ). LC n-3 PUFA may lower inflammatory burden in a number of ways: by inhibiting the conversion of LA to more pro-inflammatory eicosanoids by substrate competition, being converted themselves to less potent pro-inflammatory eicosanoids, modulation of transcription factor activation, inhibiting the expression of vascular cell adhesion molecules and cytokines, and through the inflammation-resolving properties of their oxygenated metabolites( Reference Calder 11 ). The lack of sensitivity of measurements of circulating inflammatory biomarkers, and also the large variability due to hyper-responsivity to short-term infections, has up to now hindered efforts to build a body of evidence for a role of LC n-3 PUFA in modulating chronic, low-grade inflammation in the context of CVD( Reference Skulas-Ray 89 ). The relatively recent detection of a diverse array of oxygenated PUFA metabolites presents a whole new line of investigation with respect to the anti-inflammatory effects of marine fatty acids. Some of the lipid mediators derived from LC n-3 PUFA, termed specialised pro-resolving mediators (SPM), act in an autacoid manner to resolve inflammation (Fig. 2). SPM play a functional role in ending acute inflammatory events by inhibition of neutrophil influx to the site of trauma, counter-regulating pro-inflammatory cytokines and stimulating resolving macrophages to clear the products of the inflammatory response, thereby allowing the injured area to heal( Reference Serhan 90 ). Protectin-D1 (originally termed neuroprotectin) is thought to be important in inhibiting proinflammatory gene expression and promoting nerve regeneration in neural tissue, thereby protecting neurons from inflammation-related injury in a DHA-dependent manner( Reference Bazan, Molina and Gordon 12 , Reference Bazan, Musto and Knott 91 ). DHA-derived neuroprostanes, F4 isoprostane-like compounds formed non-enzymatically through free radical-catalysed reactions, are also thought to be significant markers of oxidative stress in neural tissue( Reference Galano, Lee and Gladine 92 ); furthermore, hepatic F4-neuroprostanes are negatively associated with the extent of atherosclerotic plaque( Reference Gladine, Newman and Durand 93 ), inhibit inflammatory cell signalling in macrophages( Reference Gladine, Laurie and Giulia 94 ) and may have cardiac arrhythmic effects( Reference Roy, Oger and Thireau 95 ).

Fig. 2. Overview of the hypothesised role of membrane PUFA profiles in the production of pro-inflammatory and inflammation-resolving oxygenated lipid mediators. In addition to inhibition of arachidonic acid (ARA)-derived pro-inflammatory eicosanoid production, higher proportions of membrane phospholipid long chain (LC) n-3 PUFA may increase availability of LC n-3 PUFA available for enzymic oxygenation to lipid mediators that contribute to the resolution of an acute inflammatory response( Reference Serhan 90 ). ALA, α-linolenic acid; COX, cyclooxygenase; CYP450, cytochrome P450; HDHA, hydroxyl-DHA; HEPE, hydroxyeicosapentaenoic acid; LA, linoleic acid; LOX, lipoxygenase; PLA2, phospholipase A2; SPM, specialised pro-resolving mediators.

SPM, namely E- and D- series resolvins (RvD1 and RvE1), the DHA-derived (neuro)protectin-D1 and maresin (MaR1), are released in nano- and pico-molar concentrations at sites of local inflammation, can be detected in ex vivo cultured mononuclear cells following EPA + DHA supplementation( Reference Wang, Hjorth and Vedin 96 ) and sometimes resolvins can be detected in human plasma although concentrations are not responsive to supplementation( Reference Mas, Croft and Zahra 97 – Reference Mas, Barden and Burke 100 ). Large changes in other postprandial and fasting oxygenated PUFA metabolites have been reported in response to fish oil supplementation( Reference Barden, Mas and Croft 99 , Reference Schuchardt, Schmidt and Kressel 101 ). But the lipid mediator profiles of unsupplemented populations remain undetermined, particularly those who have very low or zero habitual dietary LC n-3 PUFA intakes. We investigated whether the vegans in our cross-sectional study also had lower circulating concentrations of oxygenated EPA and DHA metabolites, since this might have implications for their ability to resolve acute and chronic inflammation. It was observed that vegans had significantly lower plasma concentrations of EPA- and DHA-derived lipid mediators compared with omnivores, including 18-HEPE, 17-HDHA and 14-HDHA, likely precursor markers for RvE1, RvD1 and MaR1 availability, respectively( Reference Pinto, Sanders and Kendall 80 ). Although circulating plasma concentrations of lipid mediators are likely to be an insensitive marker of capacity for autacoid release and activity of SPM in specific inflamed sites in the nervous and cardiovascular systems, higher concentrations of precursor markers of SPM bioavailability (18-HEPE, 17-HDHA and 14-HDHA) may indicate greater capacity for conversion to SPM at times of need, with clear functional implications for populations with low tissue EPA and DHA stores.

The accumulating evidence suggests that tissue LC n-3 PUFA are crucial in moderating inflammatory responses in the cardiovascular system. Consequently individuals with no dietary intake of marine n-3 PUFA may be at risk of incurring inflammatory-related neuronal and cardiovascular damage at a greater rate than fish-consumers. An adverse LC n-3 PUFA-derived lipid mediator profile may also be implicated in impaired haemostatic function in vegetarians( Reference Mezzano, Muñoz and Martínez 102 ). However, presently these ideas remain strictly hypothetical. Health-conscious non-fish-consuming populations may also have a greater bioavailability of ALA- and linoleic acid (LA; 18 : 2n-6)-derived lipid mediators that may have cytoprotective effects( Reference Ramsden, Ringel and Feldstein 103 , Reference Kumar, Gupta and Anilkumar 104 ), although this may not be applicable to the majority of the non-fish-eating population. Few of these lipid mediators have been fully characterised regarding their functional effects, but evidence in animal and cell models to date suggests that plant PUFA-derived oxygenated lipid mediators comprise a complex array of diverse bioactive molecules that may also induce a range of physiological effects in various tissues( Reference Choque, Catheline and Rioux 105 – Reference Nicolaou, Mauro and Urquhart 107 ).

Alternative sources for non-fish consumers?

Soya and rapeseed oils are particularly rich in ALA, with the main dietary sources of ALA being cereal-based products, cooking oils and spreading fats, and vegetables. The high concentrations in oilseed crops presents a potentially easy, sustainable and cheap alternative source of n-3 PUFA, but the evidence for a protective effect against CVD is weaker in comparison with marine n-3 fatty acids( Reference Fleming and Kris-Etherton 108 ). Populations in Europe and the USA consume 3–9 % of energy as LA( 16 , 109 ). Dietary intake of ALA has proven difficult to assess due to methodological limitations associated with accurate fatty acid composition data in food databases, but intakes are estimated to be much lower (0·3–0·8 % energy)( 16 , 109 ) than LA intakes, which would limit the amount of endogenous LC n-3 PUFA production from ALA( Reference Rosell, Lloyd-Wright and Appleby 57 ). Reports are conflicting as to whether vegans/vegetarians consume more ALA than omnivores/fish-eaters( Reference Sanders 49 , Reference Welch, Shakya-Shrestha and Lentjes 50 , Reference Kornsteiner, Singer and Elmadfa 110 ). Dietary LA intakes on the other hand tend to be higher in vegetarians/vegans than omnivores( Reference Sanders 49 , Reference Welch, Shakya-Shrestha and Lentjes 50 ), which may also limit conversion of ALA to EPA through substrate competition( Reference Liou, King and Zibrik 111 ). Furthermore, supplementation with additional ALA in vegans appears to be ineffective in increasing conversion to LC n-3 PUFA( Reference Fokkema, Brouwer and Hasperhoven 112 ) and supplementation with pre-formed EPA and DHA may be necessary for cardioprotective benefit in non-fish-eating populations.

GM crops that can yield EPA and DHA are well-advanced along the experimental process( Reference Napier, Usher and Haslam 113 ), although the first human trial using LC n-3 PUFA-rich Camelina sativa oil has only just commenced at the time of writing. The main impetus for this bioengineering research was to find a way of producing EPA- and DHA-rich oil to replace fish oils to feed farmed fish( Reference Betancor, Sprague and Usher 114 ), but the development of transgenic oilseed crops, using genes from microalgae to synthesise EPA and DHA from shorter chain PUFA, could provide an alternative to fish oil for human supplementation and food fortification. The other, already commercially available, option is DHA-only and DHA + EPA-rich microalgal oil( Reference Sarter, Kelsey and Schwartz 115 ). These LC n-3 PUFA rich algal oils have been demonstrated to increase the DHA content of phospholipids efficiently and to have TAG- and blood pressure-lowering properties( Reference Maki, Yurko-Mauro and Dicklin 116 – Reference Theobald, Goodall and Sattar 120 ). Microalgal oils are also already being used to supplement infant formula and a limited range of adult foods but the limited scale of production and high costs presently precludes any efforts to apply to large populations( Reference Chauton, Reitan and Norsker 121 ). Furthermore, little is known about what dosage and which EPA : DHA ratio is likely to be cardio-protective in disease-free populations with low ω-3 indices( Reference Cottin, Sanders and Hall 122 ). High-DHA purified fish oils are slightly more effective than high-EPA equivalents in lowering blood pressure( Reference Mori, Bao and Burke 123 ). DHA-only algal oil consumed in combination with a fatty meal appears to avoid the less desirable effects of increasing postprandial concentrations of plasma F2 isoprostanes (markers of oxidative stress produced from arachidonic acid following non-enzymatic reaction with reactive oxygen species) compared with EPA + DHA containing fish oil( Reference Purcell, Latham and Botham 124 ). However, although retroconversion of DHA to EPA is estimated at between 8 and 14 %( Reference Conquer and Holub 125 ), the functional consequences of the lack of dietary EPA against the background of plentiful dietary DHA are not known and may be significant if EPA-derived lipid mediators have any tissue specific roles in cytoprotection. It is equally possible that EPA supplementation is less effective and that DHA-only oils are sufficient to reduce risk of lethal arrhythmia. On the whole, fish oil supplementation studies to date have not considered baseline ω-3 status, which in hindsight has hindered progress towards a robust body of evidence that can be used to formulate dietary guidelines( Reference Dwyer, Rubin and Fritsche 26 ) and consequently necessitates a fresh approach to gathering new evidence on whether non-fish-consuming populations would be at reduced risk of CHD if they had access to alternative dietary sources of EPA and DHA.

Conclusion

Observational evidence suggests that non-fish-consumers may be at greater risk of CHD mortality and low EPA + DHA tissue status is associated with increased risk of cardiac events, with arrhythmia being implicated as the most likely common risk factor. Preliminary evidence presented here suggests that vegans, who have an ω-3 index of approximately 2–3 %, may have an impaired capacity to regulate HR in response to physiological demands during the day-time, and they have a distinct lipidomic profile compared with omnivores, with markedly lower circulating concentrations of LC n-3 PUFA-derived lipid mediators. However, there is a large gap in the literature regarding the effects of EPA and DHA supplementation in populations characterised by having a low ω-3 index and the relative roles of EPA and DHA remain to be determined before supplementation can be recommended. The question of determining the safest and most effective EPA : DHA ratio for optimum cardio-protection when delivering these fatty acids outside the matrix of the whole seafood seems to be imperative in the context of the small proportion of the population who are actually meeting the fish intake guidelines. Moreover, this question is even more important when considering the increasingly pressing challenges of sustainability of wild fish stocks, and the huge estimated shortfall in total EPA + DHA presently available for human consumption if global human dietary requirements are to be met( Reference Salem and Eggersdorfer 126 ).

Acknowledgements

The author is grateful to Ana-Margarida Pinto, Tom Sanders, Ana Nicolaou, Alexandra Kendall and Caroline Wheeler-Jones for collaborations and discussions that inspired the content of this review and to Sarah Berry for critical review of the initial manuscript draft.

Financial Support

None.

Conflicts of Interest

None.

Authorship

W. H. wrote the manuscript.

References

1. Burdge, GC (2006) Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot Essent Fatty Acids 75, 161–168.Google Scholar
2. Bradbury, J (2011) Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients 3, 529–554.Google Scholar
3. Chamberlain, JG (1996) The possible role of long-chain, omega-3 fatty acids in human brain phylogeny. Perspect Biol Med 39, 436–445.Google Scholar
4. Broadhurst, CL, Cunnane, SC & Crawford, MA (1998) Rift Valley lake fish and shellfish provided brain-specific nutrition for early Homo. Br J Nutr 79, 3–21.CrossRefGoogle ScholarPubMed
5. Crawford, MA, Bloom, M, Broadhurst, CL et al. (1999 ) Evidence for the unique function of docosahexaenoic acid during the evolution of the modern hominid brain. Lipids 34, S39–S47.Google Scholar
6. Michael-Titus, AT & Priestley, JV (2014) Omega-3 fatty acids and traumatic neurological injury: from neuroprotection to neuroplasticity? Trends Neurosci 37, 30–38.Google Scholar
7. Janssen, CI & Kiliaan, AJ (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res 53, 1–17.Google Scholar
8. Makrides, M, Smithers, LG & Gibson, RA (2010) Role of long-chain polyunsaturated fatty acids in neurodevelopment and growth. Nestle Nutr Workshop Ser Pediatr Program 65, 123–133; discussion 133–126.Google Scholar
9. Dyall, SC (2015) Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci 7, 52.CrossRefGoogle Scholar
10. Robson, LG, Dyall, S, Sidloff, D et al. (2010) Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol Aging 31, 678–687.Google Scholar
11. Calder, PC (2015) Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851, 469–484.CrossRefGoogle ScholarPubMed
12. Bazan, NG, Molina, MF & Gordon, WC (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 31, 321–351.Google Scholar
13. Zheng, J, Huang, T, Yu, Y et al. (2012) Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 15, 725–737.Google Scholar
14. Albert, CM, Campos, H, Stampfer, MJ et al. (2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346, 1113–1118.Google Scholar
15. Marchioli, R, Barzi, F, Bomba, E et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105, 1897–1903.Google Scholar
16. EFSA Panel on Dietetic Products N, and Allergies (NDA) (2010) Scientific opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA J 8, 107.Google Scholar
17. Sinclair, HM (1953) The diet of Canadian Indians and Eskimos. Proc Nutr Soc 12, 69–82.Google Scholar
18. Dyerberg, J & Bang, HO (1979) Lipid metabolism, atherogenesis, and haemostasis in Eskimos: the role of the prostaglandi n-3 family. Haemostasis 8, 227–233.Google Scholar
19. Bang, HO, Dyerberg, J & Nielsen, AB (1971) Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1, 1143–1145.Google Scholar
20. Mozaffarian, D & Wu, JH (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58, 2047–2067.CrossRefGoogle ScholarPubMed
21. Chowdhury, R, Warnakula, S, Kunutsor, S et al. (2014) Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med 160, 398–406.Google Scholar
22. Rizos, EC, Ntzani, EE, Bika, E et al. (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308, 1024–1033.Google Scholar
23. Burr, ML, Fehily, AM, Gilbert, JF et al. (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2, 757–761.CrossRefGoogle ScholarPubMed
24. Tavazzi, L, Maggioni, AP, Marchioli, R et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223–1230.Google Scholar
25. von Schacky, C (2014) Omega-3 index and cardiovascular health. Nutrients 6, 799–814.CrossRefGoogle ScholarPubMed
26. Dwyer, JT, Rubin, KH, Fritsche, KL et al. (2016) Creating the future of evidence-based nutrition recommendations: case studies from lipid research. Adv Nutr 7, 747–755.Google Scholar
27. Wu, JH & Mozaffarian, D (2014) ω−3 fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle. Heart 100, 530–533.Google Scholar
28. Rice, HB, Bernasconi, A, Maki, KC et al. (2016) Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot Essent Fatty Acids 107, 30–42.Google Scholar
29. Smith, CE, Follis, JL, Nettleton, JA et al. (2015) Dietary fatty acids modulate associations between genetic variants and circulating fatty acids in plasma and erythrocyte membranes: meta-analysis of nine studies in the CHARGE consortium. Mol Nutr Food Res 59, 1373–1383.CrossRefGoogle ScholarPubMed
30. Al-Hilal, M, AlSaleh, A, Maniou, Z et al. (2013) Genetic variation at the FADS1-FADS2 gene locus influences delta-5 desaturase activity and LC-PUFA proportions after fish oil supplement. J Lipid Res 54, 542–551.Google Scholar
31. AlSaleh, A, Maniou, Z, Lewis, FJ et al. (2014) ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr 9, 362.Google Scholar
32. Grenon, SM, Conte, MS, Nosova, E et al. (2013) Association between n-3 polyunsaturated fatty acid content of red blood cells and inflammatory biomarkers in patients with peripheral artery disease. J Vasc Surg 58, 1283–1290.CrossRefGoogle ScholarPubMed
33. Harris, WS, Sands, SA, Windsor, SL et al. (2004) Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation. Circulation 110, 1645–1649.Google Scholar
34. Harris, WS & Von Schacky, C (2004) The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 39, 212–220.Google Scholar
35. Kleber, ME, Delgado, GE, Lorkowski, S et al. (2016) Omega-3 fatty acids and mortality in patients referred for coronary angiography. The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis 252, 175–181.Google Scholar
36. Browning, LM, Walker, CG, Mander, AP et al. (2012) Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clinic Nutr 96, 748–758.Google Scholar
37. Walker, CG, Browning, LM, Mander, AP et al. (2014) Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. British J Nutr 111, 679–689.Google Scholar
38. Cao, J, Schwichtenberg, KA, Hanson, NQ et al. (2006) Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids. Clin Chem 52, 2265–2272.Google Scholar
39. Dunstan, JA, Mori, TA, Barden, A et al. (2004) Effects of n-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition. Eur J Clin Nutr 58, 429–437.Google Scholar
40. Siscovick, DS, Raghunathan, TE, King, I et al. (1995) Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 274, 1363–1367.Google Scholar
41. Block, RC, Harris, WS, Reid, KJ et al. (2008) EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. Atherosclerosis 197, 821–828.Google Scholar
42. Key, TJ, Fraser, GE, Thorogood, M et al. (1999) Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 70, 516S–524S.CrossRefGoogle ScholarPubMed
43. Huang, T, Yang, B, Zheng, J et al. (2012) Cardiovascular disease mortality and cancer incidence in vegetarians: a meta-analysis and systematic review. Ann Nutr Metab 60, 233–240.Google Scholar
44. Kwok, CS, Umar, S, Myint, PK et al. (2014) Vegetarian diet, Seventh Day Adventists and risk of cardiovascular mortality: a systematic review and meta-analysis. Int J Cardiol 176, 680–686.Google Scholar
45. Key, TJ, Appleby, PN & Rosell, MS (2006) Health effects of vegetarian and vegan diets. Proc Nutr Soc 65, 35–41.Google Scholar
46. Bradbury, KE, Crowe, FL, Appleby, PN et al. (2015) Serum concentrations of cholesterol, apolipoprotein A-I and apolipoprotein B in a total of 1694 meat-eaters, fish-eaters, vegetarians and vegans. Eur J Clin Nutr 69, 1180.Google Scholar
47. Appleby, PN, Davey, GK & Key, TJ (2002) Hypertension and blood pressure among meat eaters, fish eaters, vegetarians and vegans in EPIC-Oxford. Public Health Nutr 5, 645–654.Google Scholar
48. Sanders, TA (2014) Plant compared with marine n-3 fatty acid effects on cardiovascular risk factors and outcomes: what is the verdict? Am J Clinic Nutr 100, Suppl. 1, 453S–458S.Google Scholar
49. Sanders, TA (2009) DHA status of vegetarians. Prostaglandins Leukot Essent Fatty Acids 81, 137–141.Google Scholar
50. Welch, AA, Shakya-Shrestha, S, Lentjes, MA et al. (2010) Dietary intake and status of n-3 polyunsaturated fatty acids in a population of fish-eating and non-fish-eating meat-eaters, vegetarians, and vegans and the product-precursor ratio [corrected] of alpha-linolenic acid to long-chain n-3 polyunsaturated fatty acids: results from the EPIC-Norfolk cohort. Am J Clin Nutr 92, 1040–1051.Google Scholar
51. Snowdon, DA (1988) Animal product consumption and mortality because of all causes combined, coronary heart disease, stroke, diabetes, and cancer in Seventh-day Adventists. Am J Clin Nutr 48, 739–748.Google Scholar
52. Beeson, WL, Mills, PK, Phillips, RL et al. (1989) Chronic disease among Seventh-day Adventists, a low-risk group. Rationale, methodology, and description of the population. Cancer 64, 570–581.Google Scholar
53. Berkel, J & de Waard, F (1983) Mortality pattern and life expectancy of Seventh-Day Adventists in the Netherlands. Int J Epidemiol 12, 455–459.Google Scholar
54. Orlich, MJ, Singh, PN, Sabaté, J et al. (2013) Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA Intern Med 173, 1230–1238.Google Scholar
55. Appleby, PN, Crowe, FL, Bradbury, KE et al. (2016) Mortality in vegetarians and comparable nonvegetarians in the United Kingdom. Am J Clin Nutr 103, 218–230.Google Scholar
56. Crowe, FL, Appleby, PN, Travis, RC et al. (2013) Risk of hospitalization or death from ischemic heart disease among British vegetarians and nonvegetarians: results from the EPIC-Oxford cohort study. Am J Clin Nutr 97, 597–603.Google Scholar
57. Rosell, MS, Lloyd-Wright, Z, Appleby, PN et al. (2005) Long-chain n-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. Am J Clin Nutr 82, 327–334.Google Scholar
58. Key, TJ, Appleby, PN, Spencer, EA et al. (2009) Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford). Am J Clin Nutr 89, 1613S–1619S.Google Scholar
59. Schöttker, B, Jorde, R, Peasey, A et al. (2014) Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 348, g3656.Google Scholar
60. Vaishnav, S, Stevenson, R, Marchant, B et al. (1994) Relation between heart rate variability early after acute myocardial infarction and long-term mortality. Am J Cardiol 73, 653–657.Google Scholar
61. Quintana, M, Storck, N, Lindblad, LE et al. (1997) Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study. Eur Heart J 18, 789–797.Google Scholar
62.(1996) Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 17, 354–381.Google Scholar
63. Tsuji, H, Larson, MG, Venditti, FJ Jr et al. (1996) Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94, 2850–2855.Google Scholar
64. Algra, A, Tijssen, JG, Roelandt, JR et al. (1993) Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death. Circulation 88, 180–185.Google Scholar
65. Christensen, JH (2011) Omega-3 polyunsaturated Fatty acids and heart rate variability. Front Physiol 2, 84.CrossRefGoogle ScholarPubMed
66. Mozaffarian, D, Stein, PK, Prineas, RJ et al. (2008) Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation 117, 1130–1137.CrossRefGoogle ScholarPubMed
67. Geelen, A, Zock, PL, Swenne, CA et al. (2003) Effect of n-3 fatty acids on heart rate variability and baroreflex sensitivity in middle-aged subjects. Am Heart J 146, E4.CrossRefGoogle ScholarPubMed
68. Dyerberg, J, Eskesen, DC, Andersen, PW et al. (2004) Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 58, 1062–1070.Google Scholar
69. Christensen, JH, Christensen, MS, Dyerberg, J et al. (1999) Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 70, 331–337.Google Scholar
70. Svensson, M, Schmidt, EB, Jorgensen, KA et al. (2007) The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis. J Ren Nutr 17, 243–249.Google Scholar
71. Christensen, JH, Korup, E, Aaroe, J et al. (1997) Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 79, 1670–1673.Google Scholar
72. O'Keefe, JH Jr, Abuissa, H, Sastre, A et al. (2006) Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 97, 1127–1130.Google Scholar
73. Christensen, JH, Gustenhoff, P, Korup, E et al. (1996) Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 312, 677–678.Google Scholar
74. Hamaad, A, Kaeng Lee, W, Lip, GYH et al. (2006) Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in stable post myocardial infarction patients. Cardiovasc Drugs Ther 20, 359–364.Google Scholar
75. DeGiorgio, CM, Miller, P, Meymandi, S et al. (2008) n-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. Epilepsy Behav 13, 681–684.Google Scholar
76. Xin, W, Wei, W & Li, XY (2013) Short-term effects of fish-oil supplementation on heart rate variability in humans: a meta-analysis of randomized controlled trials. Am J Clin Nutr 97, 926–935.Google Scholar
77. Verkerk, AO, den Ruijter, HM, Bourier, J et al. (2009) Dietary fish oil reduces pacemaker current and heart rate in rabbit. Heart Rhythm 6, 1485–1492.Google Scholar
78. Billman, GE (2013) The effects of omega-3 polyunsaturated fatty acids on cardiac rhythm: a critical reassessment. Pharmacol Ther 140, 53–80.Google Scholar
79. Mozaffarian, D, Geelen, A, Brouwer, IA et al. (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.CrossRefGoogle ScholarPubMed
80. Pinto, AM, Sanders, TAB, Kendall, AC et al. (2017) A comparison of heart rate variability, n-3 PUFA status and lipid mediator profile in age- and BMI-matched middle-aged vegans and omnivores. British J Nutr 117, 669–685.Google Scholar
81. Thies, F, Garry, JM, Yaqoob, P et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361, 477–485.Google Scholar
82. Dyall, SC & Michael-Titus, AT (2008) Neurological benefits of omega-3 fatty acids. Neuromol Med 10, 219–235.CrossRefGoogle ScholarPubMed
83. Papaioannou, VE, Verkerk, AO, Amin, AS et al. (2013) Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness. Curr Cardiol Rev 9, 82–96.Google Scholar
84. Lanza, GA, Sgueglia, GA, Cianflone, D et al. (2006) Relation of heart rate variability to serum levels of C-reactive protein in patients with unstable angina pectoris. Am J Cardiol 97, 1702–1706.Google Scholar
85. Malave, HA, Taylor, AA, Nattama, J et al. (2003) Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. Chest 123, 716–724.Google Scholar
86. Farzaneh-Far, R, Harris, WS, Garg, S et al. (2009) Inverse association of erythrocyte n-3 fatty acid levels with inflammatory biomarkers in patients with stable coronary artery disease: the Heart and Soul Study. Atherosclerosis 205, 538–543.Google Scholar
87. Ferrucci, L, Cherubini, A, Bandinelli, S et al. (2006) Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. J Clin Endocrinol Metab 91, 439–446.Google Scholar
88. Fontes, JD, Rahman, F, Lacey, S et al. (2015) Red blood cell fatty acids and biomarkers of inflammation: a cross-sectional study in a community-based cohort. Atherosclerosis 240, 431–436.Google Scholar
89. Skulas-Ray, AC (2015) Omega-3 fatty acids and inflammation: a perspective on the challenges of evaluating efficacy in clinical research. Prostaglandins Other Lipid Mediat 116–117, 104–111.Google Scholar
90. Serhan, CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92–101.Google Scholar
91. Bazan, NG, Musto, AE & Knott, EJ (2011) Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol Neurobiol 44, 216–222.Google Scholar
92. Galano, JM, Lee, JC, Gladine, C et al. (2015) Non-enzymatic cyclic oxygenated metabolites of adrenic, docosahexaenoic, eicosapentaenoic and α-linolenic acids; bioactivities and potential use as biomarkers. Biochim Biophys Acta 1851, 446–455.Google Scholar
93. Gladine, C, Newman, JW, Durand, T et al. (2014) Lipid profiling following intake of the omega 3 fatty acid DHA identifies the peroxidized metabolites F4-neuroprostanes as the best predictors of atherosclerosis prevention. PLoS ONE 9, e89393.Google Scholar
94. Gladine, C, Laurie, JC, Giulia, C et al. (2014) Neuroprostanes, produced by free-radical mediated peroxidation of DHA, inhibit the inflammatory response of human macrophages. Free Radic Biol Med 75, Suppl. 1, S15.Google Scholar
95. Roy, J, Oger, C, Thireau, J et al. (2015) Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid. Free Radic Biol Med 86, 269–278.Google Scholar
96. Wang, X, Hjorth, E, Vedin, I et al. (2015) Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. J Lipid Res 56, 674–681.Google Scholar
97. Mas, E, Croft, KD, Zahra, P et al. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476–1484.Google Scholar
98. Barden, AE, Mas, E, Croft, KD et al. (2015) Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. Am J Clin Nutr 102, 1357–1364.Google Scholar
99. Barden, A, Mas, E, Croft, KD et al. (2014) Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res 55, 2401–2407.Google Scholar
100. Mas, E, Barden, A, Burke, V et al. (2016) A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin Nutr 35, 331–336.Google Scholar
101. Schuchardt, JP, Schmidt, S, Kressel, G et al. (2014) Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men. Prostaglandins Leukot Essent Fatty Acids 90, 27–37.Google Scholar
102. Mezzano, D, Muñoz, X, Martínez, C et al. (1999) Vegetarians and cardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 81, 913–917.Google Scholar
103. Ramsden, CE, Ringel, A, Feldstein, AE et al. (2012) Lowering dietary linoleic acid reduces bioactive oxidized linoleic acid metabolites in humans. Prostaglandins Leukot Essent Fatty Acids 87, 135–141.Google Scholar
104. Kumar, N, Gupta, G, Anilkumar, K et al. (2016) 15-Lipoxygenase metabolites of α-linolenic acid, [13-(S)-HPOTrE and 13-(S)-HOTrE], mediate anti-inflammatory effects by inactivating NLRP3 inflammasome. Sci Rep 6, 31649.Google Scholar
105. Choque, B, Catheline, D, Rioux, V et al. (2014) Linoleic acid: between doubts and certainties. Biochimie 96, 14–21.Google Scholar
106. Harizi, H, Corcuff, JB & Gualde, N (2008) Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 14, 461–469.Google Scholar
107. Nicolaou, A, Mauro, C, Urquhart, P et al. (2014) Polyunsaturated fatty acid-derived lipid mediators and T cell function. Front Immunol 5, 75.Google Scholar
108. Fleming, JA & Kris-Etherton, PM (2014) The evidence for α-linolenic acid and cardiovascular disease benefits: comparisons with eicosapentaenoic acid and docosahexaenoic acid. Adv Nutr 5, 863S–876S.Google Scholar
109.US Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center, Food Surveys Research Group and US 1002 Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2013) What We Eat in America. NHANES 2009-2010 Data: Dietary Interview - Total Nutrients Intakes, First Day (DR1TOT_F). Available from https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2009 (accessed April 2017).Google Scholar
110. Kornsteiner, M, Singer, I & Elmadfa, I (2008) Very low n-3 long-chain polyunsaturated fatty acid status in Austrian vegetarians and vegans. Ann Nutr Metab 52, 37–47.Google Scholar
111. Liou, YA, King, DJ, Zibrik, D et al. (2007) Decreasing Linoleic Acid with Constant α-Linolenic Acid in Dietary Fats Increases (n-3) Eicosapentaenoic Acid in Plasma Phospholipids in Healthy Men. J Nutr 137, 945–952.Google Scholar
112. Fokkema, MR, Brouwer, DA, Hasperhoven, MB et al. (2000) Short-term supplementation of low-dose gamma-linolenic acid (GLA), alpha-linolenic acid (ALA), or GLA plus ALA does not augment LCP omega 3 status of Dutch vegans to an appreciable extent. Prostaglandins Leukot Essent Fatty Acids 63, 287–292.Google Scholar
113. Napier, JA, Usher, S, Haslam, RP et al. (2015) Transgenic plants as a sustainable, terrestrial source of fish oils. Eur J Lipid Sci Technol 117, 1317–1324.Google Scholar
114. Betancor, MB, Sprague, M, Usher, S et al. (2015) A nutritionally-enhanced oil from transgenic Camelina sativa effectively replaces fish oil as a source of eicosapentaenoic acid for fish. Sci Rep 5, 8104.Google Scholar
115. Sarter, B, Kelsey, KS, Schwartz, TA et al. (2015) Blood docosahexaenoic acid and eicosapentaenoic acid in vegans: associations with age and gender and effects of an algal-derived omega-3 fatty acid supplement. Clin Nutr 34, 212–218.Google Scholar
116. Maki, KC, Yurko-Mauro, K, Dicklin, MR et al. A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia. Prostaglandins, Leukot Essent Fatty Acids 91, 141–148.Google Scholar
117. Conquer, JA & Holub, BJ (1996) Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 126, 3032–3039.Google Scholar
118. Geppert, J, Kraft, V, Demmelmair, H et al. (2005) Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial. Lipids 40, 807–814.Google Scholar
119. Bernstein, AM, Ding, EL, Willett, WC et al. (2012) A meta-analysis shows that docosahexaenoic acid from algal oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease. J Nutr 142, 99–104.Google Scholar
120. Theobald, HE, Goodall, AH, Sattar, N et al. (2007) Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women. J Nutr 137, 973–978.Google Scholar
121. Chauton, MS, Reitan, KI, Norsker, NH et al. (2015) A techno-economic analysis of industrial production of marine microalgae as a source of EPA and DHA-rich raw material for aquafeed: research challenges and possibilities. Aquaculture 436, 95–103.Google Scholar
122. Cottin, SC, Sanders, TA & Hall, WL (2011) The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 70, 215–231.Google Scholar
123. Mori, TA, Bao, DQ, Burke, V et al. (1999) Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 34, 253–260.Google Scholar
124. Purcell, R, Latham, SH, Botham, KM et al. (2014) High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F-2 alpha concentrations relative to a control high-oleic acid meal: a randomized controlled trial. Am J Clin Nutr 100, 1019–1028.Google Scholar
125. Conquer, JA & Holub, BJ (1997) Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 32, 341–345.Google Scholar
126. Salem, N & Eggersdorfer, M (2015) Is the world supply of omega-3 fatty acids adequate for optimal human nutrition? Curr Opin Clin Nutr Metab Care 18, 147–154.Google Scholar
127. Cottin, SC, Alsaleh, A, Sanders, TAB et al. (2016) Lack of effect of supplementation with EPA or DHA on platelet-monocyte aggregates and vascular function in healthy men. Nutr Metab Cardiovas. 26, 743–751.Google Scholar
128. Johnston, DT, Deuster, PA, Harris, WS et al. (2013) Red blood cell omega-3 fatty acid levels and neurocognitive performance in deployed U.S. Servicemembers. Nutr Neurosci 16, 30–38.Google Scholar
129. Reidlinger, DP, Darzi, J, Hall, WL et al. (2015) How effective are current dietary guidelines for cardiovascular disease prevention in healthy middle-aged and older men and women? A randomized controlled trial. Am J Clin Nutr 101, 922–930.Google Scholar
130. Sanders, TA, Lewis, F, Slaughter, S et al. (2006) Effect of varying the ratio of n-6 to n-3 fatty acids by increasing the dietary intake of alpha-linolenic acid, eicosapentaenoic and docosahexaenoic acid, or both on fibrinogen and clotting factors VII and XII in persons aged 45–70 y: the OPTILIP study. Am J Clin Nutr 84, 513–522.Google Scholar
131. Sanders, TA, Gleason, K, Griffin, B et al. (2006) Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women. Br J Nutr 95, 525–531.Google Scholar
132. Agren, JJ, Törmälä, ML, Nenonen, MT et al. (1995) Fatty acid composition of erythrocyte, platelet, and serum lipids in strict vegans. Lipids 30, 365–369.Google Scholar
133. Fokkema, MR, Brouwer, DA, Hasperhoven, MB et al. (2000) Polyunsaturated fatty acid status of Dutch vegans and omnivores. Prostaglandins Leukot Essent Fatty Acids 63, 279–285.Google Scholar
134. Rajaram, S, Haddad, EH, Mejia, A et al. (2009) Walnuts and fatty fish influence different serum lipid fractions in normal to mildly hyperlipidemic individuals: a randomized controlled study. Am J Clin Nutr 89, 1657S–1663S.Google Scholar
135. Sanders, TA, Ellis, FR & Dickerson, JW (1978) Studies of vegans: the fatty acid composition of plasma choline phosphoglycerides, erythrocytes, adipose tissue, and breast milk, and some indicators of susceptibility to ischemic heart disease in vegans and omnivore controls. Am J Clin Nutr 31, 805–813.Google Scholar
136.Blausen Gallery (2014) Wikiversity J Med. Available from https://en.wikiversity.org/wiki/File:Blausen_0259_CoronaryArteryDisease_02.png (accessed April 2017).Google Scholar
Figure 0

Table 1. Erythrocyte EPA and DHA (% or absolute concentrations) of meat- and fish-consumers (omnivores), vegetarians and vegans

Figure 1

Fig. 1. Theoretical schematic showing how low long chain n-3 PUFA intakes may oppose the cardioprotective effects of vegetarian/vegan diets, resulting in an equivalent risk of CHD mortality (A). The majority of the UK population eats little or no fish and may be at risk of low ω-3 status. Without the counterbalancing cardio-protective qualities of a vegetarian/vegan diet, this could lead to an increased risk of CHD mortality mediated by arrhythmia (B). Picture of artery attributed to ‘Blausen gallery 2014’(136).

Figure 2

Fig. 2. Overview of the hypothesised role of membrane PUFA profiles in the production of pro-inflammatory and inflammation-resolving oxygenated lipid mediators. In addition to inhibition of arachidonic acid (ARA)-derived pro-inflammatory eicosanoid production, higher proportions of membrane phospholipid long chain (LC) n-3 PUFA may increase availability of LC n-3 PUFA available for enzymic oxygenation to lipid mediators that contribute to the resolution of an acute inflammatory response(90). ALA, α-linolenic acid; COX, cyclooxygenase; CYP450, cytochrome P450; HDHA, hydroxyl-DHA; HEPE, hydroxyeicosapentaenoic acid; LA, linoleic acid; LOX, lipoxygenase; PLA2, phospholipase A2; SPM, specialised pro-resolving mediators.